drugset / Trial / NCT00524056

A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor

NCT00524056

Phase 2 Completed 62 enrolled SK Life Science, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness, safety and tolerability of carisbamate treatment for the signs, symptoms, and impairment associated with Essential Tremor (ET) compared to placebo treatment. The secondary objective is to evaluate the effect of carisbamate treatment on indicators of affect and mood in patients who have ET compared to placebo treatment.

Timeline

Start
2007-08
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Carisbamate Small molecule 200 mg Oral

Indications